United States - English - NLM (National Library of Medicine)

organon llc - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary. therapy is usually instituted in children between the ages of 4 and 9. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately treated with human gonadotropins. - prior hypersensitivity reactions to human gonadotropins, including hcg, or any of the excipients (see adverse reactions). - high serum fsh, indicating primary gonadal failure in women. - presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). - tumors of the hypothalamus or pituitary gland and ovary, breast, or uterus in females and breast or prostate in males. - malformations of the reproductive organs incompatible with pregnancy. - fibroid tumors of the uterus incompatible with pregnancy. - abnormal vaginal bleeding of undetermined origin.

Canada - English - Health Canada

emd serono, a division of emd inc., canada - choriogonadotropin alfa - solution - 250mcg - choriogonadotropin alfa 250mcg - gonadotropins and antigonadotropins

Canada - English - Health Canada

emd serono, a division of emd inc., canada - choriogonadotropin alfa - solution - 250mcg - choriogonadotropin alfa 250mcg - gonadotropins and antigonadotropins

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - chorionic gonadotropin (unii: 20ed16gheb) (chorionic gonadotropin - unii:20ed16gheb), choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - gonadotrophin, chorionic 400 [iu] in 5 ml - indications for use prepuberal gilts: p.g. 600 is indicated for induction of fertile estrus (heat) in healthy prepuberal (non-cycling) gilts over five and one-half months of age and weighing at least 85 kg (187 lb.). sows at weaning: p.g. 600 is indicated for induction of estrus in healthy weaned sows experiencing delayed return to estrus.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sdn. bhd. - choriogonadotropin alfa -

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - choriogonadotropin alfa - injection, solution - 250 mcg - choriogonadotropin alfa 250 mcg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - choriogonadotropin alfa - solution for injection - 500microgram/1ml

United States - English - NLM (National Library of Medicine)

a-s medication solutions - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary. therapy is usually instituted in children between the ages of 4 and 9. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately treated with human gonadotropins. - prior hypersensitivity reactions to human gonadotropins, including hcg, or any of the excipients (see adverse reactions). - high serum fsh, indicating primary gonadal failure in women. - presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). - tumors of the hypothalamus or pituitary gland and ovary, breast, or uterus in females and breast or prostate in males. - malformations of the reproductive organs incompatible with pregnancy. - fibroid tumors of the uterus incompatible with pregnancy. - abnormal vaginal bleeding of undetermined origin.

Israel - English - Ministry of Health

merck serono ltd - follitropin alfa - solution for injection - follitropin alfa 600 iu/ml - follitropin alfa - follitropin alfa - in adult women:• anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate.• stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift).• follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l.in adult men:• follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - choriogonadotropin alfa - solution for injection - 500microgram/1ml